First Novel Monoclonal Antibody Against COVID-19 Enters Clinical Trials - HospiMedica 12-Jun-2020

First Novel Monoclonal Antibody Against COVID-19 Enters Clinical Trials - HospiMedica

Tychan (Singapore), a clinical-stage biotechnology company, is initiating Phase 1 clinical trials to evaluate TY027, the first novel monoclonal antibody (mAb) that specifically targets SARS-CoV-2.